Pay, get the data, go to court. Alas, we can’t pay.
Statements like this are a disservice to any serious investor. NP has been more than able to raise funds on an as needed basis and to infer that he cannot do so now and that is the cause of Cytodyn withholding payment to Amarex is fallacious.
Our company has funds to carry us over into 2022 and with the 200 million additional shares being voted on, we will have the ability to fund the anticipated outlays to produce more product. It was pretty clear in the EG conference yesterday, the private placement route will continue to be utilized to bring in the monthly overhead and ongoing trialing expenses through our first serious revenue production event.